McGuireWoods advised Avenue Therapeutics Inc., a specialty pharmaceutical
company focused on the development and commercialization of therapies for
treating central nervous system diseases, in its $12 million follow-on
underwritten public offering of securities that closed Oct. 11, 2022.
In the offering, underwritten by Aegis Capital Corp. as sole bookrunning
manager, Avenue Therapeutics sold approximately 3,636,365 common and
pre-funded “units.” Each common unit consists of one share of common stock
and one warrant to purchase one share of common stock. Each pre-funded unit
consists of one pre-funded warrant to purchase one share of common stock
and one warrant to purchase one share of common stock.
Rakesh Gopalan and counsel
David Wolpa led the deal team, which also included New York associate Samar Khan and Richmond associate
Latasha James. All are members of the firm’s Securities & Capital Markets
Department. Charlotte partner
Sabrina Conyers advised on tax issues.
“We were pleased to assist Avenue Therapeutics in this transaction, which
will further the company’s important work developing treatments for central
nervous system diseases and bringing these products to market,” Gopalan
McGuireWoods’ capital markets team has earned global recognition for its
representation of corporate issuers and underwriters in complex corporate
and securities matters, repeatedly ranking among the top law firms for debt
and equity issuances in authoritative league tables.